Close Menu

NEW YORK (GenomeWeb) – Precipio said on Friday that it expects a 200 percent year-over-year increase in fourth quarter revenues, driven primarily by its pathology diagnostic services and pharma projects run in its lab.

For the three-month period ended Dec. 31, 2017 Precipio posted preliminary revenues of $945,000 compared with $316,000 generated in the year-ago quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.